Publications & Presentations in the therapeutic area :

Integrating tracer kinetic data with absolute protein concentration measurements in a systems pharmacology model

Maanen E.v., Steeg T.v., Stone J., Dobrowolska J., Michener M., Savage M., Kennedy M., Bateman R., Kleijn H. and Danhof M., Integrating tracer kinetic data with absolute protein concentration measurements in a systems pharmacology model. Application to the APP pathway in CMP rhesus monkeys., PAGE.(2014) [Link to publication]

Quantification of the effect of AZD5213

Ackaert O., Steeg T.v., Hannesdottir K., Alexander R., Raudibaugh K., Kugler A. and Vis P., Quantification of the effect of AZD5213 on sleep in patients with Alzheimer’s disease or mild cognitive impairment using a two-state Markov model. PAGE.(2014) [Link to publication]

A systems pharmacology model of the APP processing pathway in Alzheimer’s Disease

Maanen E.v., Steeg T.v., Ahsman M., Savage M.J., Michener M.S., Kleijn H.J., Danhof M. and Stone J., A systems pharmacology model of the APP processing pathway in Alzheimer’s Disease. ACoP.(2013) [Link to publication]

A Phase 2 Safety and Tolerability Study to Investigate the Effect of AZD5213 on Sleep

Hannesdottir K., Minkwitz M., Raudibaugh K., Vis P., Ackaert O. and Alexander R. A Phase 2 Safety and Tolerability Study to Investigate the Effect of AZD5213 on Sleep in Subjects with Mild Cognitive Impairment and Mild Alzheimer’s Disease. AAIC (2013)

The impact of P-gp functionality

Westerhout J., Smeets J., Danhof M. and de Lange E.C., The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid, J Pharmacokinet Pharmacodyn, 29: 29, 2013. [Link to publication]

A hidden Markov model to assess drug-induced sleep fragmentation

Diack C., Ackaert O., Ploeger B.A., Graaf P.H.v.d., R.Gurrel, Ivarsson M. and Fairman D., A hidden Markov model to assess drug-induced sleep fragmentation. PAGE.(2012) [Link to publication]

Quantification of the Drug Effect and Exploration of Mechanism of Action of Two NMDA Channel Blockers

Wallsten C., Ackaert O., Ekerot P., Snelder N., Quirk M., Fonck C. and Ploeger B., Quantification of the Drug Effect and Exploration of Mechanism of Action of Two NMDA Channel Blockers, AZD6765 and Ketamine, Using Mouse EEG Data PAGE.(2012) [Link to publication]

An Integrated Mechanistic Model

Stone J.A., Maanen E.v., Ahsman M., Steeg T.v., Savage M.J., Michener M.S. and Kleijn H., An Integrated Mechanistic Model to Interrelate CSF Aβ40, Aβ42, sAPPβ, and sAPPα Response to β and γ-secretase Inhibitors in Rhesus Monkey. AAIC.(2012)

A step-wise analysis of multiple biomarkers drives the development of a Semi-Mechanistic Comprehensive Model. Application to modulation of Amyloid-β

Maanen E.v., Stone J.A., Steeg T.v., Ahsman M., Savage M.J., Michener M.S. and Kleijn H., A step-wise analysis of multiple biomarkers drives the development of a Semi-Mechanistic Comprehensive Model. Application to modulation of Amyloid-β. PAGE.(2012) [Link to publication]

Quantification of Antidepressant and Sedative Effect of Two NMDA Channel Blockers

Bergmann K., Ackaert O., Maanen E.v., Snelder N., Maciag C., Quirk M., Wallsten C. and Ploeger B., Quantification of Antidepressant and Sedative Effect of Two NMDA Channel Blockers, AZD6765 and Ketamine, in an Animal Model of Depression Using Count Data. PAGE.(2012)